SUNNYVALE, Calif.-- Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis, has appointed Adam J. Simon, Ph.D., to its Board of Advisors. Dr. Simon is a world expert in the field of Alzheimer’s disease biomarkers and has significant expertise in the development of in-vitro diagnostics.
“Dr. Simon will play an important role in the development of our LymPro diagnostic blood test for Alzheimer’s disease,” said Gerald E. Commissiong, President and Chief Executive Officer of Amarantus BioScience. “He is a recognized leader in the discovery of Alzheimer’s biomarkers, and has advised both major pharmaceutical companies and early stage research companies on their clinical programs and regulatory submissions. Dr. Simon is also an entrepreneur in his own right, and understands the specific challenges and opportunities we face here at Amarantus.”
Dr. Simon is the founder and president of AJ Simon Enterprises, LLC, a consulting firm serving pharmaceutical and biotechnology clients, including Bristol Myers Squibb. He is also the founder and chief executive officer of Cerora, Inc., a healthcare information technology company focused on developing medical devices and services to assess brain health, including Traumatic Brain Injury. Earlier in his career he spent more than 13 years at Merck Research Laboratories, where he served as a Senior Research Fellow in Integrative Systems Neuroscience and Biomarkers and in Alzheimer’s disease research. He has also been a visiting scientist at Princeton University.
Dr. Simon received Bachelor’s degrees in Physics and Mathematics from the University of Rochester. He received a Doctorate in Physics from the University of Chicago. He holds four patents related to medical research, and has published more than 60 articles in scientific and medical journals.
About Amarantus BioScience
Amarantus BioScience, Inc. is a development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury, Ischemic Heart Disease and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. The Company also owns intellectual property and licenses for the diagnosis of Parkinson's disease and Alzheimer's disease. For further information please visit www.Amarantus.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible progress of the MANF technology in testing for Parkinson’s disease, as well as statements about expectations, plans and prospects of the development of Amarantus' diagnostic product candidates for Parkinson’s and Alzheimer’s disease. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks associated with development of therapeutic drug candidates, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements. Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.
Don Markley, Senior Vice President
Source: Amarantus BioScience, Inc.